Literature DB >> 21677139

Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.

Aled Clayton1, Saly Al-Taei, Jason Webber, Malcolm D Mason, Zsuzsanna Tabi.   

Abstract

Extracellular adenosine is elevated in cancer tissue, and it negatively regulates local immune responses. Adenosine production from extracellular ATP has attracted attention as a mechanism of regulatory T cell-mediated immune regulation. In this study, we examined whether small vesicles secreted by cancer cells, called exosomes, contribute to extracellular adenosine production and hence modulate immune effector cells indirectly. We found exosomes from diverse cancer cell types exhibit potent ATP- and 5'AMP-phosphohydrolytic activity, partly attributed to exosomally expressed CD39 and CD73, respectively. Comparable levels of activity were seen with exosomes from pleural effusions of mesothelioma patients. In such fluids, exosomes accounted for 20% of the total ATP-hydrolytic activity. Exosomes can perform both hydrolytic steps sequentially to form adenosine from ATP. This exosome-generated adenosine can trigger a cAMP response in adenosine A(2A) receptor-positive but not A(2A) receptor-negative cells. Similarly, significantly elevated cAMP was also triggered in Jurkat cells by adding exosomes with ATP but not by adding exosomes or ATP alone. A proportion of healthy donor T cells constitutively express CD39 and/or CD73. Activation of T cells by CD3/CD28 cross-linking could be inhibited by exogenously added 5'AMP in a CD73-dependent manner. However, 5'AMP converted to adenosine by exosomes inhibits T cell activation independently of T cell CD73 expression. This T cell inhibition was mediated through the adenosine A(2A) receptor. In summary, the data highlight exosome enzymic activity in the production of extracellular adenosine, and this may play a contributory role in negative modulation of T cells in the tumor environment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677139     DOI: 10.4049/jimmunol.1003884

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  213 in total

1.  Cancer cells use exosomes as tools to manipulate immunity and the microenvironment.

Authors:  Aled Clayton
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  CD73 promotes tumor growth and metastasis.

Authors:  Bin Zhang
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 3.  Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis.

Authors:  David Lu; Paul A Insel
Journal:  Am J Physiol Cell Physiol       Date:  2013-12-18       Impact factor: 4.249

4.  Modulation of cellular function through immune-activated exosomes.

Authors:  Lynn Pulliam; Archana Gupta
Journal:  DNA Cell Biol       Date:  2015-05-06       Impact factor: 3.311

Review 5.  Biomimetic and synthetic interfaces to tune immune responses.

Authors:  Anusha Garapaty; Julie A Champion
Journal:  Biointerphases       Date:  2015-09-15       Impact factor: 2.456

Review 6.  Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.

Authors:  Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Jonatha Wruck; Fernanda Dos Anjos; Débora Tavares de Resende E Silva; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini
Journal:  Inflamm Res       Date:  2021-04-27       Impact factor: 4.575

7.  CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function.

Authors:  Jong Joo Lee; Hyun Jeong Jeong; Mee Kum Kim; Won Ryang Wee; Won Woo Lee; Seung U Kim; Changmin Sung; Yung Hun Yang
Journal:  Purinergic Signal       Date:  2013-09-17       Impact factor: 3.765

8.  Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7.

Authors:  Andrea Vergani; Sara Tezza; Francesca D'Addio; Carmen Fotino; Kaifeng Liu; Monika Niewczas; Roberto Bassi; R Damaris Molano; Sonja Kleffel; Alessandra Petrelli; Antonio Soleti; Enrico Ammirati; Maria Frigerio; Gary Visner; Fabio Grassi; Maria E Ferrero; Domenico Corradi; Reza Abdi; Camillo Ricordi; Mohamed H Sayegh; Antonello Pileggi; Paolo Fiorina
Journal:  Circulation       Date:  2012-12-18       Impact factor: 29.690

9.  Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo.

Authors:  Ferdinando Pucci; Mikael J Pittet
Journal:  Clin Cancer Res       Date:  2013-02-20       Impact factor: 12.531

10.  Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-κB signal pathway.

Authors:  Meng Zhou; Zhifa Wen; Feng Cheng; Jie Ma; Weixia Li; Hongyan Ren; Yemeng Sheng; Huixia Dong; Liwei Lu; Hong-Ming Hu; Li-Xin Wang
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.